Investors Purchase High Volume of Teva Pharmaceutical Industries Call Options (NYSE:TEVA)

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) saw some unusual options trading activity on Tuesday. Stock investors purchased 27,298 call options on the stock. This is an increase of approximately 82% compared to the typical daily volume of 14,998 call options.

Insider Activity at Teva Pharmaceutical Industries

In other news, insider Placid Jover sold 14,150 shares of the firm’s stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $31.67, for a total transaction of $448,130.50. Following the sale, the insider owned 6,774 shares of the company’s stock, valued at $214,532.58. This trade represents a 67.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Mark Sabag sold 62,102 shares of the company’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $30.14, for a total value of $1,871,754.28. Following the transaction, the insider directly owned 224,940 shares of the company’s stock, valued at approximately $6,779,691.60. This trade represents a 21.64% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 920,901 shares of company stock worth $30,056,789 over the last 90 days. Insiders own 0.55% of the company’s stock.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Phoenix Financial Ltd. grew its holdings in shares of Teva Pharmaceutical Industries by 9.4% during the 3rd quarter. Phoenix Financial Ltd. now owns 41,295,244 shares of the company’s stock valued at $834,164,000 after purchasing an additional 3,533,800 shares during the last quarter. National Pension Service increased its position in Teva Pharmaceutical Industries by 24.2% during the 3rd quarter. National Pension Service now owns 2,073,293 shares of the company’s stock worth $41,881,000 after purchasing an additional 404,526 shares in the last quarter. Public Sector Pension Investment Board lifted its stake in Teva Pharmaceutical Industries by 11.5% in the 3rd quarter. Public Sector Pension Investment Board now owns 670,467 shares of the company’s stock valued at $13,543,000 after purchasing an additional 69,000 shares during the last quarter. Oak Harvest Investment Services acquired a new stake in Teva Pharmaceutical Industries in the third quarter valued at approximately $1,010,000. Finally, Harel Insurance Investments & Financial Services Ltd. grew its stake in shares of Teva Pharmaceutical Industries by 12.9% during the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 37,696,690 shares of the company’s stock worth $761,455,000 after buying an additional 4,306,363 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms recently weighed in on TEVA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, January 21st. Bank of America raised their price objective on Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. Truist Financial boosted their target price on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a report on Wednesday, February 18th. Jefferies Financial Group increased their price target on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, January 6th. Finally, The Goldman Sachs Group raised their price target on Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the company a “buy” rating in a report on Monday, February 9th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $37.67.

Teva Pharmaceutical Industries Price Performance

TEVA stock traded up $1.77 during midday trading on Tuesday, reaching $30.12. The company had a trading volume of 6,555,325 shares, compared to its average volume of 9,099,524. Teva Pharmaceutical Industries has a 1-year low of $12.47 and a 1-year high of $37.35. The stock has a 50 day moving average price of $32.26 and a 200-day moving average price of $27.54. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.04 and a quick ratio of 0.80. The company has a market capitalization of $34.63 billion, a price-to-earnings ratio of 25.10, a price-to-earnings-growth ratio of 9.62 and a beta of 0.72.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Wednesday, January 28th. The company reported $0.96 EPS for the quarter, beating the consensus estimate of $0.65 by $0.31. The firm had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.36 billion. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. The business’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same period last year, the firm earned $0.71 EPS. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. Equities research analysts expect that Teva Pharmaceutical Industries will post 2.5 earnings per share for the current year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.